Latest News

NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment


Shares of NanoViricides Inc.

jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment. There are currently no approved or authorized therapies for monkeypox, though the Food and Drug Administration said last month that it’s allowing prescriptions of the antiviral Tpoxx through a compassionate-use pathway. Tpoxx is made by Siga Technologies Inc.
NanoViricides’ stock has slid 33.8% so far this year, while the broader S&P 500

is down 12.8%.

Paramount Revenue Rose 19% on ‘Top Gun,’ Streaming Service

Previous article

Crocs stock dips after earnings as company cuts forecast

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News